Firefighters may face increased risk of brain cancer due to chemical exposure: Study
Firefighters may face a heightened risk of developing brain cancer due to their persistent exposure to certain chemicals, a new study has found.
In a set of patients who had gliomas — the most common type of malignant brain tumor — cancer-causing gene mutations linked to toxic exposures were more prevalent in firefighters than in individuals from other professions, according to the study, published on Monday in Cancer.
The compounds in question, called haloalkanes, are found in flame retardants, fire extinguishers, refrigerants and pesticides and have previously been associated with a specific gene mutation that causes gliomas, the researchers noted.
'Glioma is the most common malignant primary brain tumor and is associated with significant morbidity and mortality,' the authors warned.
Examining the histories of 35 participants in the University of California Adult Glioma Study, the scientists — from multiple researcher institutes across the country — determined that 17 individuals had an occupational history of firefighting.
These participants worked as firefighters for an average of 22 years and received their diagnoses about seven years after their least reported occupational exposure, per the study.
Looking for the presence of a specific mutational 'signature,' or pattern, linked to haloalkanes exposure, the researchers found that the firefighters were much more likely to have the signature than the other 18 participants.
Within the non-firefighter contingent, the mutational signatures appeared more in individuals whose careers also possibly exposed them to haloalkanes, including painters and auto-mechanics.
Senior author Elizabeth Claus, a professor at Yale University School of Public Health, acknowledged in a statement that the study's results were only preliminary and that a much larger data set across a broader range of professions is needed to confirm the findings.
But she and her colleagues also stressed that pinpointing potential links to exposure-related mutations in cancers 'is extremely important because they may inform public health intervention.'
Such knowledge, they explained, could help researchers develop strategies to prevent the gene mutations that cause cancer formation. And in the haloalkane scenario, awareness about the possible connection could also help firefighters to prevent certain exposures, the scientists added.
'Identifying exposure to such mutational agents is important to inform public health intervention strategies and pinpoint occupational hazards that may be avoidable,' Claus said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 hours ago
- USA Today
Check out this interactive map of the early universe, considered largest ever created
Check out this interactive map of the early universe, considered largest ever created An intricate astral tapestry, the map gives stargazers digital views of the ancient cosmos in unprecedented detail and breadth. A team of astronomers have put together the largest, most detailed map of the universe ever created – and you can explore it now. The interactive online map, created using data from NASA's James Webb Space Telescope, details some 800,000 galaxies across a vast cosmic distance – which in astronomy amounts to peering back in time. In fact, some of the galaxies are so far away, they appear as they existed not long after the Big Bang. Depicting a section of the universe known as the COSMOS-Web field, the new map is far more expansive than even the iconic Hubble Ultra Deep Field, a view of 10,000 galaxies NASA released in 2004. Spanning nearly all of cosmic time, the new map has the potential to challenge existing notions of the infant universe, the astronomers who created it claimed in a press release. The best part? The interactive map is available for the public to use. See interactive map of the universe A team of international scientists who are part of the Cosmic Evolution Survey program (COSMOS) created and released the map of the universe Thursday, June 5. Compiled from more than 10,000 images of COSMOS-Web – the largest observing program of James Webb Space Telescope's first year in orbit – the map covers about three times as much space as the moon takes up when viewed from Earth. That makes it the largest contiguous image available from Webb, according to the Rochester Institute of Technology, whose Jeyhan Kartaltepe is a lead researcher on the project. An intricate astral tapestry, the map gives stargazers digital views of the ancient cosmos in unprecedented detail and breadth. Scrolling and zooming in can take users some 13.5 billion years back in time when the universe was in its infancy and stars, galaxies and black holes were still forming. 'If you had a printout of the Hubble Ultra Deep Field on a standard piece of paper, our image would be slightly larger than a 13-foot by 13-foot-wide mural, at the same depth," Caitlin Casey, a physicist at the University of California, Santa Barbara and co-lead for the COSMOS project, said in a statement. "It's really strikingly large.' Explore the interactive map here. NASA's Webb telescope gathers data for online map Using its powerful resolution and infrared capabilities, the James Webb Space Telescope observed a region of space known as the COSMOS-web field, which scientists have been surveying for years. The raw data from the COSMOS field observations was made publicly available once it was collected by Webb, but that didn't mean it was easily accessible. That's why the COSMOS project spent two years creating the map from Webb's raw data to make it more digestible for amateur astronomers, researchers and even the general public. "In releasing the data to the public, the hope is that other astronomers from all over the world will use it to, among other things, further refine our understanding of how the early universe was populated and how everything evolved to the present day," according to a statement from UC Santa Barbara. What is the James Webb Space Telescope? The James Webb Space Telescope, which launched in 2021, far surpasses the abilities of the Hubble Space Telescope, launched 35 years ago in 1990. Orbiting the sun rather than Earth, the Webb is outfitted with a gold-coated mirror and powerful infrared instruments to observe the cosmos like no instrument before. Since reaching the cosmos, Webb has not only facilitated countless scientific breakthroughs in astrophysics, but it also has produced gorgeous images of planets and other celestial objects, including star-forming regions. In March, NASA also deployed into orbit its SPHEREx telescope to collect data on more than 450 million galaxies. Scientists say the SPHEREx observatory will be able to get a wider view of the galaxy – identifying objects of scientific interest that telescopes like Hubble and Webb can then study up close. SPHEREx became operational in May, constantly snapping images of the cosmos. Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@
Medscape
6 hours ago
- Medscape
Emerging Treatment Strategies Benefit Older Adults With ALL
CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors and poor treatment tolerance. But a variety of treatment approaches beyond chemotherapy-only regimens are making inroads in this challenging disease. That's the message Elias Jabbour, MD, of MD Anderson Cancer Center in Houston, delivered during an educational session at American Society of Clinical Oncology (ASCO) 2025. 'Our data show that 5-year overall survival (OS) for patients aged 65+ years remains less than 20, despite all the treatment advances we've seen in the past decade,' Jabbour told attendees. Referring to a review article he co-authored that was published recently in JAMA Oncology , Jabbour noted that these poorer outcomes are due to both disease characteristics and patient characteristics. Regarding disease characteristics, ALL in older adults is more likely to be of B-cell origin, with a greater co-expression of myeloid antigens. It may also have more adverse cytogenetic abnormalities, including Philadelphia positivity, t(4;11), low hypoploidy/near triploidy. It may also have less high hyperdiploidy, t(12;21), and normal karyotype. These traits make ALL in older adults more refractory to primary chemotherapy, Jabbour said. Patient characteristics that contribute to poorer outcomes in ALL include lower male to female ratio, reduced renal function, and a tendency to have worse mucositis. A history of cardiovascular disease (CVD) is common, Jabbour said, noting the importance of establishing a baseline ejection fraction before beginning treatment. With an estimated past malignancy rate of 8%-16% in this population, these factors all combine to lead to more early deaths, Jabbour added. Jabbour noted that immunotherapies like blinatumomab and inotuzumab have shown promise, with similar response rates in older and younger patients. He summarized results from the trials that established immunotherapy as standard of care in relapsed or refractory ALL. Data published in The New England Journal of Medicine (NEJM) in 2017 showed that the median OS for patients in the blinatumomab group was 7.7 months vs 4.0 months for those in the standard chemotherapy group. More patients had a marrow complete response (CR) in the blinatumomab group than in the chemotherapy group, at 44% vs 25%. Data published in the NEJM in 2016 found that patients who received inotuzumab were more likely to have a marrow CR than those in the chemotherapy group (74% vs 31%). Jabbour also shared data from two studies that stratified patients by age. With blinatumomab, the overall response rate (ORR) was 56% in patients aged 65 years or older compared with 46% in patients younger than 65 years, according to data published in Cancer. Jabbour also shared data from one of his own trials published in Cancer that found that inotuzumab had an ORR of 81% in patients aged 55 years or older vs 80% in those younger than 55 years. 'Then, we asked if we could take these drugs to the frontline and spare the need for intensive chemotherapy for older patients and those with comorbidities,' Jabbour said. 'In 2010, we designed the mini-hyper-CVD regimen with significantly trimmed chemotherapy, then added inotuzumab. Subsequently we added blinatumomab as a consolidation approach and the 10-year follow-up data looked good.' Jabbour shared a list of seven teams of researchers currently testing frontline blinatumomab and inotuzumab combinations in newly diagnosed ALL in older adults. 'All are reporting promising results compared to historical data,' he said. 'We've made progress and survival of older patients is approaching 50% where historically were at 20% overall survival.' The next frontier has been to remove chemotherapy altogether, Jabbour said. 'As investigators, we have to make every effort to move into a chemotherapy-free approach for these vulnerable patients.' This chemotherapy-free approach combining blinatumomab and inotuzumab with TKIs has yielded encouraging results, Jabbour said. 'We know immunotherapies are better than chemotherapy; therefore, it's time to combine them with TKIs,' he said. 'We must prevent central nervous system (CNS) relapses because patients are living longer, and these CNS relapses are what's limiting our progress.' Jabbour highlighted the TKI ponatinib, noting that his and other groups have shown that the use of ponatinib has increased minimal residual disease (MRD)-negative CRs, as well as significantly increasing event-free survival. Ongoing trials are evaluating further optimizations, including integrating CAR T-cell therapy. 'We are measuring MRD by next-generation sequencing (NGS) at 10-6. If a patient is NGS MRD-negative, then we maintain the TKI and do not go for transplant,' Jabbour said. 'In patients who are NGS MRD-positive, we are offering them CAR T cells. If they become MRD-negative, we maintain the TKI; otherwise, we go for transplant.' That means, Jabbour said, that ALL has gone from a disease where transplant was the only way to cure patients to potentially being able to offer CAR T and the promise of finite therapy to these patients. 'We are walking away from chemotherapy because the combination of blinatumomab and a TKI are inducing survival at 4 years of 80%-90%,' he said. 'Moving forward, it's time to integrate immunotherapy fully into the frontline setting, along with bispecific antibody-drug conjugates and CAR T cells.' Jabbour noted that randomized studies are ongoing, with results expected by 2027. 'I hope we will then have a new standard of care for these patients,' he later told Medscape Medical News . Jabbour disclosed having relationships with AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Astellas Pharma, Bristol Myers Squibb, Genentech, Incyte, Pfizer, and Takeda.
Scientific American
6 hours ago
- Scientific American
Brain Implant Lets Man with ALS Speak and Sing with His ‘Real Voice'
A man with a severe speech disability is able to speak expressively and sing using a brain implant that translates his neural activity into words almost instantly. The device conveys changes of tone when he asks questions, emphasizes the words of his choice and allows him to hum a string of notes in three pitches. The system — known as a brain–computer interface (BCI) — used artificial intelligence (AI) to decode the participant's electrical brain activity as he attempted to speak. The device is the first to reproduce not only a person's intended words but also features of natural speech such as tone, pitch and emphasis, which help to express meaning and emotion. In a study, a synthetic voice that mimicked the participant's own spoke his words within 10 milliseconds of the neural activity that signalled his intention to speak. The system, described today in Nature, marks a significant improvement over earlier BCI models, which streamed speech within three seconds or produced it only after users finished miming an entire sentence. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. 'This is the holy grail in speech BCIs,' says Christian Herff, a computational neuroscientist at Maastricht University, the Netherlands, who was not involved in the study. 'This is now real, spontaneous, continuous speech.' Real-time decoder The study participant, a 45-year-old man, lost his ability to speak clearly after developing amyotrophic lateral sclerosis, a form of motor neuron disease, which damages the nerves that control muscle movements, including those needed for speech. Although he could still make sounds and mouth words, his speech was slow and unclear. Five years after his symptoms began, the participant underwent surgery to insert 256 silicon electrodes, each 1.5-mm long, in a brain region that controls movement. Study co-author Maitreyee Wairagkar, a neuroscientist at the University of California, Davis, and her colleagues trained deep-learning algorithms to capture the signals in his brain every 10 milliseconds. Their system decodes, in real time, the sounds the man attempts to produce rather than his intended words or the constituent phonemes — the subunits of speech that form spoken words. 'We don't always use words to communicate what we want. We have interjections. We have other expressive vocalizations that are not in the vocabulary,' explains Wairagkar. 'In order to do that, we have adopted this approach, which is completely unrestricted.' The team also personalized the synthetic voice to sound like the man's own, by training AI algorithms on recordings of interviews he had done before the onset of his disease. The team asked the participant to attempt to make interjections such as 'aah', 'ooh' and 'hmm' and say made-up words. The BCI successfully produced these sounds, showing that it could generate speech without needing a fixed vocabulary. Freedom of speech Using the device, the participant spelt out words, responded to open-ended questions and said whatever he wanted, using some words that were not part of the decoder's training data. He told the researchers that listening to the synthetic voice produce his speech made him 'feel happy' and that it felt like his 'real voice'. In other experiments, the BCI identified whether the participant was attempting to say a sentence as a question or as a statement. The system could also determine when he stressed different words in the same sentence and adjust the tone of his synthetic voice accordingly. 'We are bringing in all these different elements of human speech which are really important,' says Wairagkar. Previous BCIs could produce only flat, monotone speech. 'This is a bit of a paradigm shift in the sense that it can really lead to a real-life tool,' says Silvia Marchesotti, a neuroengineer at the University of Geneva in Switzerland. The system's features 'would be crucial for adoption for daily use for the patients in the future.'
